Radiopharmacy in Saxony
Radiopharmacy is developing into a key technology in nuclear medicine cancer treatment. Saxony's ecosystem, particularly in the Dresden region, is ideally positioned for this.
International market leaders and innovation drivers
A powerful network of companies and research institutions with a focus on radiopharmaceuticals has been established in Saxony. The growth nucleus was the former GDR core research center, today's HZDR, which met the demand for radio-pharmaceutical preparations even before reunification. It develops new substances for therapy and diagnostics as well as software algorithms for imaging with positron emission tomography (PET) and is working on equipping innovative immunotherapeutics with additional radioactive emitters.
-
A Leading Global Supplier of Radiopharmaceutical Precursors
-
World’s First Full-Service CRO for Nuclear Medicine
-
Experts in Radiopharmaceutical Analysis
-
Customized Hot Cell Solutions and In-Cell Equipment
-
Handling of Radioactive Materials
-
R&D on More Efficient Visualization, Characterization, and Treatment of Tumors
-
A Pioneer for Personalized Medicine
-
Novel Biomarkers and Theranostic Solutions
-
Radiation Protection, Analysis, and Disposal of Radioactive Materials
Map of Radiopharmacy Facilities in Saxony
In Dresden in particular, the field of radiopharmacy boasts a combination of stakeholders and expertise that is unique in Germany, spanning the entire value chain all the way to patients at Dresden University Hospital. Here, among other things, nuclear medicine is being advanced through innovation, opening up new avenues in the fight against cancer.
nukliD® - Radiopharmacy Cluster Dresden
nukliD® is a dynamic network in Dresden that specializes in radiopharmacy and offers a unique combination of expertise in this field throughout Germany. The network innovatively advances nuclear medicine and opens up new perspectives for cancer treatment.
The close cooperation between the partners in the network results in new approaches in nuclear medicine that improve the precision and effectiveness of cancer treatment. In addition, the network is committed to political activities and lobbying for better framework conditions in order to promote and accelerate progress in cancer research and treatment.
Your contact persons
Tina Jaehnig
Industry, Innovation & Marketing
+49-351-2138 138
Barbara Weigert
Investor Services
+49-351-2138 153